HCA Healthcare

HCA

Valor de mercado US$ 99,3 bi

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

HCA Healthcare remains a "Buy," supported by strong revenue growth and favorable demographic trends in healthcare demand. Despite some margin pressures from payer mix shifts, HCA's revenue per equivalent admission rose 6% and occupancy improved year-over-year. Management anticipates 2026 revenue growth to $77–$79.5 billion, though net income and EBITDA guidance have been revised slightly lower.

HF Sinclair, Accenture and FirstCash post impressive gains as Zacks research portfolios highlight standout performers amid market uncertainty and shifting investor sentiment.

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext.

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 3Q 2026 Earnings Call When: Tuesday, October 27, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, [email protected] If you are unable to listen during the live webcast, the call will.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.